Join the club for FREE to access the whole archive and other member benefits.

GSK on artificial intelligence drive to develop drugs faster

The more people looking at clever new ways to beat cancer the better


Key points from article :

GlaxoSmithKline is ramping up its use of artificial intelligence to develop medicines of the future.

AI can speed the process up and increase the success rate of new medicines from 10% currently.

Recruiting 80 AI specialists, across London, Heidelberg, San Francisco, Philadelphia and Boston, by the end of 2020.

Includes PhD or master’s researchers in London under a new fellows programme.

Functional genomics looks at hundreds of millions of data points from genetic databases.

Mentioned in this article:

Click on resource name for more details.

GlaxoSmithKline (GSK)

Research and develop pharmaceutical medicines, vaccines and consumer healthcare products

Topics mentioned on this page:
AI in Healthcare, Big Pharma